natgillin/translations-raw huggingface dataset:
Hjælpestof, som behandleren skal være opmærksom på Hver hård kapsel indeholder 105,91 mg lactosemonohydrat.
Each hard capsule contains 105.91 mg lactose monohydrate.
Dette fald i atazanavir Cmin kan påvirke effekten af atazanavir negativt.
This decrease in atazanavir cmin, might negatively impact the efficacy of atazanavir.
Voksne patienter, der ikke tidligere har været i antiretroviral behandling Studie 138 er et internationalt, randomiseret, åbent, prospektivt multicenter-studie med ikke tidligere antiretroviralt behandlede patienter, der sammenligner atazanavir/ritonavir (300 mg/100 mg én gang dagligt) med lopinavir/ritonavir (400 mg/100 mg 2 gange dagligt), hver i kombination med en fast dosis tenofovirdisoproxilfumarat/emtricitabin (300 mg/200 mg tabletter én gang dagligt).
Study 138 is an international randomised, open-label, multicenter, prospective trial of treatment naïve patients comparing atazanavir /ritonavir (300 mg/100 mg once daily) to lopinavir/ritonavir (400 mg/100 mg twice daily), each in combination with fixed dose tenofovir disoproxil fumarate/emtricitabine (300 mg/200 mg tablets once daily).
Indinavir resulterer i indirekte ukonjugeret hyperbilirubinæmi pga. UGT-hæmning.
Indinavir is associated with indirect unconjugated hyperbilirubinaemia due to inhibition of UGT.
Efter en 26-30 ugers induktionsfase med atazanavir 300 mg + ritonavir 100 mg én gang dagligt og to NRTI'er havde ikke-boostet atazanavir 400 mg én gang dagligt og to NRTI'er, som blev administreret i en 48-ugers vedligeholdelsesfase (n=87) i et åbent, randomiseret, komparativt studie, samme antivirale virkning som atazanavir + ritonavir og to NRTI'er (n=85) hos hiv-inficerede forsøgspersoner med fuldt supprimeret hiv-replikation.
In an open-label, randomised, comparative study following a 26- to 30-week induction phase with atazanavir 300 mg + ritonavir 100 mg once daily and two NRTIs, unboosted atazanavir 400 mg once daily and two NRTIs administered during a 48-week maintenance phase (n=87) had similar antiviral efficacy compared with atazanavir + ritonavir and two NRTIs (n=85) in HIV infected subjects with fully suppressed HIV replication, as assessed by the proportion of subjects with HIV RNA < 50 copies/ml: 78% of subjects on unboosted atazanavir and two NRTIs compared with 75% on atazanavir + ritonavir and two NRTIs.
Behandlingsnaive atazanavir kapsler/ritonavir (300 mg/100 mg én gang dagligt) n=16
Treatment-Naive atazanavir Capsules/ritonavir (300 mg/100 mg once daily) n=16
- Der er rapporteret om hududslæt og kløe, som i nogle tilfælde kan være alvorligt.
- Skin rash, itching that may occasionally be severe has been reported.
Atazanavir Krka 150 mg hårde kapsler Atazanavir Krka 200 mg hårde kapsler Atazanavir Krka 300 mg hårde kapsler
Atazanavir Krka 150 mg hard capsules Atazanavir Krka 200 mg hard capsules Atazanavir Krka 300 mg hard capsules atazanavir
Ikke-boostet Atazanavir Krka må ikke anvendes til patienter med svært nedsat leverfunktion.
Unboosted Atazanavir Krka must not be used in patients with severe hepatic impairment.
LIPIDSÆNKENDE MIDLER HMG-CoA-reduktasehæmmere Simvastatin
LIPID LOWERING AGENTS HMG-CoA reductase inhibitors Simvastatin Lovastatin
Hos et lille antal patienter uden en funktionel CYP2C19-allel forventes signifikant øget voriconazol eksponering (se pkt.
In a small number of patients without a functional CYP2C19 allele, significantly increased voriconazole exposures are expected (see section 4.5).
Immunsupprimerende midler Ciclosporin
Immunosuppressants Cyclosporin Tacrolimus Sirolimus
Kapslens hætte er påtrykt A300 med hvidt.
The capsule cap is imprinted with white mark A300.
Sofosbuvir 400 mg / velpatasvir 100 mg /voxilaprevir 100 mg enkeltdosis* (atazanavir 300 mg / ritonavir 100 mg 1 gang dagligt)
Sofosbuvir 400 mg / velpatasvir 100 mg /voxilaprevir 100 mg single dose*
Samtidig administration af voriconazol og atazanavir med ritonavir frarådes medmindre det vurderes, at fordel/risiko-forholdet for patienten berettiger brug af voriconazol (se pkt.
Co-administration of voriconazole and atazanavir with ritonavir is not recommended unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see section 4.4).
Nevirapin AUC ↑26% (↑17% ↑36%) Nevirapin Cmax ↑21% (↑11% ↑32%) Nevirapin Cmin ↑35% (↑25% ↑47%)
Nevirapine AUC ↑26% (↑17% Nevirapine cmax ↑21% (↑11% Nevirapine cmin ↑35% (↑25%
(300 mg/100 mg 1 gang dagligt) n=440
(300 mg/ 100 mg once daily (n=120)
Absorption: gentagne doser af atazanavir 300 mg én gang dagligt i kombination med ritonavir 100 mg én gang dagligt sammen med et måltid gav hos hiv-inficerede patienter (n=33, kombinerede studier) et geometrisk gennemsnit (CV%) for atazanavir, Cmax på 4.466 (42%) ng/ml, med en tid til Cmax på ca. 2,5 timer.
Absorption: in HIV-infected patients (n=33, combined studies), multiple dosing of atazanavir 300 mg once daily with ritonavir 100 mg once daily with food produced a geometric mean (CV%) for atazanavir, cmax of 4466 (42%) ng/ml, with time to cmax of approximately 2.5 hours.
Samtidig administration af atazanavir med ritonavir og en protonpumpehæmmere frarådes.
Co-administration of atazanavir with ritonavir and proton pump inhibitors is not recommended.
Atazanavir Krka 150 mg og 200 mg hårde kapsler fås i beholdere med 60 hårde kapsler, i en æske.
Atazanavir Krka 150 mg and 200 mg hard capsules are available in containers containing 60 hard capsules; in a box.
Samtidig administration af atazanavir kan medføre højere salmeterolkoncentration og øget risiko for salmeterol-relaterede bivirkninger.
Co-administration with atazanavir may result in increased concentrations of salmeterol and an increase in salmeterolassociated adverse events.
Den anbefalede dosis til voksne er 300 mg Atazanavir Krka én gang dagligt sammen med 100 mg ritonavir én gang dagligt i forbindelse med et måltid og i kombination med anden hiv-medicin.
The recommended adult dose of Atazanavir Krka capsules is 300 mg once daily with 100 mg ritonavir once daily and with food, in combination with other anti-HIV medicines.
Kapslens hætte er påtrykt A200 med sort.
The capsule cap is imprinted with black mark A200.
Voriconazol AUC ↑561% (↑451% ↑699%) Voriconazol Cmax ↑438% (↑355% ↑539%) Voriconazol Cmin ↑765% (↑571%
Voriconazole AUC ↑561% Voriconazole cmax ↑438% (↑355% Voriconazole cmin ↑765% (↑571%
Atazanavir Krka uden ritonavir bør ikke overvejes hos patienter, der bliver behandlet i et baggrundsprogram med tenofovirdisoproxil og med andre samtidige lægemidler, der reducerer atazanavirs biotilgængelighed (se pkt.
Atazanavir Krka given without ritonavir should not be considered in patients treated with a backbone regimen containing tenofovir disoproxil and with other concomitant medications that reduce atazanavir bioavailability (see section 4.5 In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen) or in case of perceived challenging compliance.
Koncentrationerne af grazoprevir steg betydeligt ved samtidig administration med atazanavir/ritonavir.
Grazoprevir concentrations were greatly increased when coadministered with atazanavir/ritonavir.
*Interval på 70-143%, hvor der ikke er farmakokinetisk interaktion
*Lack of pharmacokinetics interaction bounds 70-143% Effect on atazanavir and ritonavir exposure has not been studied.
HORMONEL KONTRACEPTION Ethinylestradiol 25 μg + norgestimat (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt)
HORMONAL CONTRACEPTIVES Ethinyloestradiol 25 μg + norgestimate (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
shellac titandioxid (E171)
shellac titanium dioxide (E171) potassium hydroxide
Ethinylestradiol 35 μg + norethindron (atazanavir 400 mg 1 gang dagligt)
Ethinyloestradiol 35 µg + norethindrone (atazanavir 400 mg once daily)
Lovastatin høj grad via CYP3A4 og samtidig administration med atazanavir kan medføre øgede koncentrationer.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and coadministration with atazanavir may result in increased concentrations.
Brug af anden medicin sammen med Atazanavir Krka Du må ikke tage Atazanavir Krka sammen med visse andre lægemidler.
You must not take Atazanavir Krka with certain medicines.
Non-nukleosid reverse transkriptasehæmmere (NNRTI'er) Efavirenz 600 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily (atazanavir 400 mg once daily with ritonavir 100 mg once daily)
Hvis atazanavir/ritonavir administreres samtidigt med både tenofovirdisoproxil og en H2-receptorantagonist, anbefales dosisøgning af atazanavir til 400 mg med 100 mg ritonavir.
For patients who are taking tenofovir disoproxil, if atazanavir/ritonavir with both tenofovir disoproxil and an H2receptor antagonist are coadministered, a dose increase of atazanavir to 400 mg with 100 mg of ritonavir is recommended.
ANTIBIOTIKA Clarithromycin 500 mg 2 gange dagligt (atazanavir 400 mg 1 gang dagligt)
ANTIBIOTICS Clarithromycin 500 mg twice daily (atazanavir 400 mg once daily)
Du må ikke amme, mens du tager Atazanavir Krka.
Patients should not breast-feed while taking Atazanavir Krka.
14-OH-clarithromycin AUC ↓70% (↓74%
14-OH clarithromycin 14-OH clarithromycin AUC ↓70%
Voriconazol AUC ↓33% (↓42% ↓22%) Voriconazol Cmax ↓10% (↓22% ↓4%) Voriconazol Cmin ↓39% (↓49% ↓28%)
Voriconazole AUC ↓33% (↓42% Voriconazole cmax ↓10% (↓22% Voriconazole cmin ↓39% (↓49%
- hvis du tager et eller flere af følgende slags medicin (se også Brug af anden medicin sammen med Atazanavir Krka): - rifampicin (et antibiotikum, der bruges til at behandle tuberkulose) - astemizol eller terfenadin (bruges almindeligvis til at behandle allergiske symptomer, det er medicin som muligvis kan fås uden recept); cisaprid (bruges til at behandle tilbageløb af maveindhold, nogle gange omtalt som sure opstød); pimozid (bruges til at behandle skizofreni); quinidin eller bepridil (bruges til at korrigere hjerterytme); ergotamin, dihydroergotamin, ergonovin, methylergonovin (bruges til at behandle migræne); og alfuzosin (bruges til at behandle forstørret blærehalskirtel (prostata))
Your doctor will evaluate how severe yourliver disease is before deciding whether you can take Atazanavir Krka - if you are taking any of these medicines: see also Other medicines and Atazanavir Krka - rifampicin (an antibiotic used to treat tuberculosis) - astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland) - quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder), lurasidone (used to treat schizophrenia)
Atazanavir kan øge plasmakoncentrationen af carbamazepin på grund af CYP3A4-hæmning.
Atazanavir may increase plasma levels of carbamazepine due to CYP3A4 inhibition.
Behandlingserfarne atazanavir kapsler/ritonavir (300 mg/100 mg én gang dagligt) n=25
Treatment- Experienced atazanavir Capsules/ritonavir (300 mg/100 mg once daily) n=25
Der er anden medicin, som du ikke må tage samtidig med Atazanavir Krka.
There are other medicines that may not mix with Atazanavir Krka.
Nukleosid/nukleotid reverse transkriptasehæmmere (NRTI'er) Lamivudin 150 mg 2 gange dagligt + zidovudin 300 mg
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily (atazanavir 400 mg once daily)
ikke almindelig: muskelatrofi, artralgi, myalgi sjælden: myopati
Musculoskeletal and connective tissue disorders uncommon: muscle atrophy, arthralgia, myalgia; rare: myopathy
Koncentrationerne for elbasvir steg ved samtidig administration med atazanavir/ritonavir.
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir.
ANTINEOPLASTISKE OG IMMUNSUPRIMERENDE MIDLER Antineoplastiske midler
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics
Atazanavir Krka bør anvendes med forsigtighed til pædiatriske patienter med allerede eksisterende overledningsproblemer (andengrads- eller højere atrioventrikulær eller kompleks knude-grenblok), og kun såfremt fordelene opvejer risikoen.
In paediatric patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Krka should be used with caution and only if the benefits exceed the risk.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Atazanavir Krka 150 mg hårde kapsler Hver hård kapsel indeholder 150 mg atazanavir (som sulfat).
QUALITATIVE AND QUANTITATIVE COMPOSITION Atazanavir Krka 150 mg hard capsules Each hard capsule contains 150 mg atazanavir (as sulphate).
Samtidig administration af atazanavir og elbasvir/grazoprevir er kontraindiceret på grund af en signifikant stigning i plasmakoncentrationer af grazoprevir og en associeret potentiel stigning i risiko for ALAT-stigning (se pkt.
Co-administration of atazanavir and elbasvir/grazoprevir is contraindicated because of a significant increase in grazoprevir plasma concentrations and an associated potential increase in the risk of ALT elevations (see section
INFORMATION I BRAILLESKRIFT Atazanavir Krka 150 mg
INFORMATION IN BRAILLE Atazanavir Krka 150 mg
Didanosin AUC ↓34% (↓41% ↓27%) Didanosin Cmax ↓38% (↓48% ↓26%) Didanosin Cmin ↑25% (↓8% ↑69%)
Didanosine (with food) Didanosine AUC ↓34% (↓41% ↓27%) Didanosine cmax ↓38% (↓48% ↓26%) Didanosine cmin
INFORMATION I BRAILLESKRIFT Atazanavir Krka 200 mg
INFORMATION IN BRAILLE Atazanavir Krka 200 mg
Samtidig administration med produkter indeholdende grazoprevir, inklusive fastdosis-kombination af elbasvir/grazoprevir (anvendes til behandling af hepatitis C-infektion) (se pkt.
- grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)
Atazanavir Krka 150 mg hårde kapsler
Atazanavir Krka 150 mg hard capsules
Der bør udvises forsigtighed ved samtidig administration af verapamil og atazanavir.
Caution should be exercised when verapamil is coadministered with atazanavir.
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/19/1353/003 30 hårde kapsler
MARKETING AUTHORISATION NUMBER(S) EU/1/19/1353/003 30 hard capsules EU/1/19/1353/004 90 (3 x 30) hard capsules
INFORMATION I BRAILLESKRIFT Atazanavir Krka 300 mg
INFORMATION IN BRAILLE Atazanavir Krka 300 mg
Indehaver af markedsføringstilladelsen KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
MARKETING AUTHORISATION HOLDER KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
INDEHAVER AF MARKEDSFØRINGSTILLADELSEN KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
4.4) kan ikke-boostet Atazanavir Krka fortsættes hos patienter med let nedsat leverfunktion med en dosis på 400 mg og hos patienter med moderat nedsat leverfunktion med en reduceret dosis på 300 mg én gang dagligt sammen med føde (se pkt.
In case of withdrawal of ritonavir from the initial recommended ritonavir boosted regimen (see section 4.4), unboosted Atazanavir Krka could be maintained in patients with mild hepatic impairment at a dose of 400 mg, and in patients with moderate hepatic impairment with a reduced dose of 300 mg once daily with food (see section 5.2).
Atazanavir Krka 300 mg hårde kapsler
Atazanavir Krka 300 mg hard capsules
Hvis kombinationen af Atazanavir Krka og en protonpumpehæmmer ikke kan undgås, anbefales tæt klinisk monitorering af patienten, samtidig med at dosis af Atazanavir Krka øges til 400 mg med 100 mg ritonavir.
If the combination of Atazanavir Krka with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of Atazanavir Krka to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded.
Interaktionsmekanismen for amiodaron eller systemisk lidocain/atazanavir er CYP3A-hæmning.
The mechanism of amiodarone or systemic lidocaine/atazanavir interaction is
Hvis oral kontraception administreres samtidig med atazanavir/ritonavir, anbefales det, at det indeholder mindst
If an oral contraceptive is administered with atazanavir/ritonavir, it is recommended that the oral contraceptive contain at least 30 μg of ethinyloestradiol and that the patient be reminded of strict compliance with this contraceptive dosing regimen.
Raltegravir Cmax ↑24% Raltegravir C12t ↑77%
Raltegravir AUC ↑41% Raltegravir cmax ↑24% Raltegravir c12hr ↑77% The mechanism is UGT1A1 inhibition.
Høje doser ketoconazol og itraconazol (>200 mg/dag) frarådes.
Ketoconazole and itraconazole should be used cautiously with atazanavir /ritonavir, high doses of ketoconazole and itraconazole (>200 mg/day) are not recommended.
Samtidig administration af salmeterol og Atazanavir Krka anbefales ikke (se pkt.
Co-administration of salmeterol and Atazanavir Krka is not recommended (see section 4.5).
Samtidig administration af atazanavir med produkter indeholdende grazoprevir, inklusive elbasvir/grazoprevir i fastdosis-kombination (anvendes til behandling af hepatitis C-infektion), er kontraindiceret på grund af stigning i plasmakoncentrationerne af grazoprevir og elbasvir og den potentielle stigning i risiko for ALAT-stigning, som er associeret med stigning i koncentrationer af grazoprevir (se pkt.
Co-administration of atazanavir with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with increased grazoprevir concentrations (see section 4.3).
Atazanavir Krka en daglig dosis
Atazanavir Krka once daily dose ritonavir once daily dosea
CD4 Middelændring fra baseline, celler/mm3 ved baseline karakteristika hiv-RNA <100.000 kopier/ml
CD4 Mean Change from Baseline, cells/mm by Baseline Characteristic
Atazanavir Krka bør anvendes med forsigtighed til patienter med allerede eksisterende overledningsproblemer (andengrads- eller højere atrioventrikulær eller kompleks knude-grenblok), og kun såfremt fordelene opvejer risikoen (se pkt.
In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Krka should be used with caution and only if the benefits exceed the risk (see section 5.1).
HCV-proteasehæmmere Boceprevir 800 mg 3 gange dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt)
HCV Protease Inhibitors Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Ethinylestradiol AUC ↑48% (↑31% ↑68%) Ethinylestradiol Cmax ↑15% (↓1% ↑32%) Ethinylestradiol Cmin ↑91% (↑57% ↑133%)
Ethinyloestradiol AUC ↑48% Ethinyloestradiol cmax ↑15% (↓1% Ethinyloestradiol cmin ↑91%
a Atazanavirs maksimumkoncentration og AUC var ca. 26-40% højere i post partum perioden (4-12 uger) end observeret historisk hos hiv-smittede, ikke-gravide patienter.
a Atazanavir peak concentrations and AUCs were found to be approximately 26-40% higher during the postpartum period (4
ANTIMYKOTIKA Ketoconazol 200 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt)
ANTIFUNGALS Ketoconazole 200 mg once daily (atazanavir 400 mg once daily)
, angioødem a, urticaria, alopeci, pruritus sjælden: Stevens-Johnsons syndroma,b, vesikulobulløst udslæt, eksem, vasodilatation
common: rash; uncommon: erythemia multiformea,b, toxic skin eruptionsa,b, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome a,b angioedemaa, urticaria, alopecia, pruritus; rare: Stevens-Johnson syndrome a,b
ikke almindelig: nefrolitiasisa, hæmaturi, proteinuri, pollakisuri, interstitiel nefritis, kronisk nyresygdom a;
uncommon: nephrolithiasis a, haematuria, proteinuria, pollakiuria, interstitial nephritis; chronic kidney diseasea rare: kidney pain
Kapselskal af Atazanavir Krka 200 mg hårde kapsler Krop: titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172) og gelatine Hætte: titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), gelatine og blæk (shellac, sort jernoxid (E172), kaliumhydroxid)
Capsule shell of Atazanavir Krka 200 mg hard capsules Body: titanium dioxide (E171), yellow ferric oxide (E172), red ferric oxide (E172) and gelatine Cap: titanium dioxide (E171), yellow ferric oxide (E172), red ferric oxide (E172), gelatine and ink (shellac, black ferric oxide (E172), potassium hydroxide
Atazanavir Krka er kontraindiceret hos patienter med svær leverinsufficiens (se pkt.
Atazanavir Krka is contraindicated in patients with severe hepatic insufficiency (see sections 4.2, 4.4 and 5.2).
Der er indberettet nyresten hos patienter behandlet med atazanavir.
Kidney stones have been reported in patients taking atazanavir.
Atazanavir Krka 200 mg hårde kapsler Hver hård kapsel indeholder 200 mg atazanavir (som sulfat).
Atazanavir Krka 200 mg hard capsules Each hard capsule contains 200 mg atazanavir (as sulphate).
Det skal du vide, før du begynder at tage Atazanavir Krka Sådan skal du tage Atazanavir Krka Bivirkninger
What Atazanavir Krka is and what it is used for What you need to know before you take Atazanavir Krka How to take Atazanavir Krka Possible side effects
Norgestimat Cmax ↑68% (↑51% ↑88%) Norgestimat Cmin ↑102% (↑77% ↑131%)
Norgestimate AUC ↑85% (↑67% Norgestimate cmax ↑68% (↑51% Norgestimate cmin ↑102% (↑77%
Atazanavir Krka kan påvirke din nyrefunktion.
Atazanavir Krka may affect how well your kidneys work.
Samtidig administration af Atazanavir Krka og protonpumpehæmmere frarådes (se pkt.
Co-administration of Atazanavir Krka with proton pump inhibitors is not recommended (see section 4.5).
Pædiatriske patienter (under 3 måneder)
Paediatric patients (at least 3 months of age and weighing at least 5 kg):
ANTI-HCV MIDLER Grazoprevir 200 mg 1 gang dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt)
ANTI-HCV AGENTS Grazoprevir 200 mg once daily (atazanavir 300 mg/ ritonavir 100 mg once daily)
Interaktionsmekanismen mellem atazanavir og ritonavir er CYP3A4-hæmning.
The mechanism of interaction between atazanavir and ritonavir is CYP3A4 inhibition.
- Nyresten kan forekomme mindre hyppigt hos personer, der tager atazanavir.
- Kidney stones uncommonly happen in people taking atazanavir.
LÆGEMIDLETS NAVN Atazanavir Krka 200 mg hårde kapsler atazanavir
NAME OF THE MEDICINAL PRODUCT Atazanavir Krka 200 mg hard capsules atazanavir